Shares of ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) jumped 20% following the release of early data from its ongoing Phase 1b ...

Cantor Fitzgerald analyst Prakhar Agrawal commented on the results, stating, "Overall, a solid update by ORIC with not much to nitpick on efficacy/safety." Agrawal reiterated an Overweight rating on ...

ORIC Pharmaceuticals' ORIC-533 was promising ... In February last year, analysts at Cantor Fitzgerald noted that the global addressable market for ORC-114 was over $2.5bn, excluding China.

Tuesday, Cantor Fitzgerald reaffirmed its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC) stock, maintaining a positive outlook on the company’s future. The research firm’s analyst ...

On Monday, Cantor Fitzgerald reiterated its Overweight rating on ORIC Pharmaceuticals (NASDAQ:ORIC), currently trading at $13.39, after an incident involving a potential news leak. According to ...